PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32606981-13	2020	Furthermore, anlotinib was able to inhibit the activation of VEGFR-2/AKT and FGFR, PDGFRbeta and their downstream signaling ERK.	anlotinib	13-22	kinase insert domain protein receptor	Mus musculus	61-68	
28953502-1	2018	OBJECTIVES: AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFbeta), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3).	anlotinib	20-29	kinase insert domain protein receptor	Mus musculus	135-141	
28953502-1	2018	OBJECTIVES: AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFbeta), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3).	anlotinib	20-29	kinase insert domain protein receptor	Mus musculus	142-145	
28953502-1	2018	OBJECTIVES: AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFbeta), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3).	anlotinib	12-18	kinase insert domain protein receptor	Mus musculus	135-141	
28953502-1	2018	OBJECTIVES: AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFbeta), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3).	anlotinib	12-18	kinase insert domain protein receptor	Mus musculus	142-145